-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Folic acid: a marker of endothelial function in type 2 diabetes?
(2820) Views (459) Full article downloads
Authors: Arduino A Mangoni, Roy A Sherwood, Belinda Asonganyi, Emma L Ouldred, Stephen Thomas, Stephen HD Jackson
Published Date January 2005
Volume 2005:1(1) Pages 79 - 83
DOI: http://dx.doi.org/10.2147/VHRM.S
Arduino A Mangoni1, Roy A Sherwood2, Belinda Asonganyi2, Emma L Ouldred3, Stephen Thomas4, Stephen HD Jackson3
1Department of Clinical Pharmacology, Centre for Neuroscience, School of Medicine, Flinders University, Adelaide, SA, Australia; 2Clinical Biochemistry, King’s College Hospital, London, UK; 3Department of Health Care of the Elderly, Guy’s, King’s, and St Thomas’ School of Medicine, King’s College, London, UK; 4Department of Diabetic Medicine, King’s College Hospital, London, UK
Objectives: Endothelial dysfunction is a common feature of type 2 diabetes. Recent studies suggest that the B-vitamin folic acid exerts direct beneficial effects on endothelial function, beyond the well known homocysteine lowering effects. Therefore, folic acid might represent a novel “biomarker” of endothelial function. We sought to determine whether plasma levels of folic acid determine endothelial-dependent vasodilation in patients with type 2 diabetes.
Methods: Forearm arterial blood flow (FABF) was measured at baseline and during intrabrachial infusion of the endothelial-dependent vasodilator acetylcholine (15 µg/min) and the endothelial-independent vasodilator sodium nitroprusside (2 µg/min) in 26 type 2 diabetic patients (age 56.5 ± 0.9 years, means ± SEM) with no history of cardiovascular disease.
Results: FABF ratio (ie, the ratio between the infused and control forearm FABF) significantly increased during acetylcholine (1.10 ± 0.04 vs 1.52 ± 0.07, p < 0.001) and sodium nitroprusside (1.12 ± 0.11 vs 1.62 ± 0.06, p < 0.001) infusions. After correcting for age, gender, diabetes duration, smoking, hypertension, body mass index, microalbuminuria, glycated hemoglobin, low-density lipoprotein cholesterol, and homocysteine, multiple regression analysis showed that plasma folic acid concentration was the only independent determinant (p = 0.037, R2 = 0.22) of acetylcholine-mediated, but not sodium nitroprusside-mediated, vasodilatation.
Conclusions: Folic acid plasma concentrations determine endothelium-mediated vasodilatation in patients with type 2 diabetes. These results support the hypothesis of a direct effect of folic acid on endothelial function and the rationale for interventions aimed at increasing folic acid levels to reduce cardiovascular risk.
Keywords: folic acid, homocysteine, endothelium, type 2 diabetes
Readers of this article also read:
Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus
Premature coronary artery disease in Indians
Blood pressure and control of cardiovascular risk
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Erratum
A case of recurrent bloody tears
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




